跳至主要内容
临床试验/CTRI/2025/08/093468
CTRI/2025/08/093468尚未招募不适用

Development of a novel predictive nomogram to prevent futile surgery in gallbladder cancers a single center analysis of resected gallbladder cancers

Tata Memorial Hospital, Mumbai2 个研究点 分布在 1 个国家目标入组 1,126 人开始时间: 2025年9月8日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,126
试验地点
2
主要终点
to develop a nomogram to predict possibility of ‘futile surgery’ in gallbladder cancers

研究概览

简要总结

Gallbladder cancer (GBC) has a higher rate of occurrence in India compared to the rest of the world. Surgery to remove the gallbladder is often seen as the only way to cure GBC. Surgery ranges from a simple removal of gallbladder to major liver surgery depending on different stages of GBC. However, even after surgery, many patients (20-30 percentage) only live for about five years, and over half see the cancer come back. This raises the question if surgery is the best option for all GBC cases. Sometimes, the risks of GBC surgery can be more than the benefits and it might not help the patient to live longer or feel better. This is called ‘futile surgery’.

This study has gathered data of a large population of GBC patients to understand which patients are likely to not have any benefit from surgery. The goal of this study is to create a tool which will help doctors in identifying such patients. This will avoid unnecessary surgeries and focus on treatments which will be helpful to patients.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • All patients with histopathology proven gallbladder adenocarcinoma (GBAC)
  • All GBC patients who underwent a curative resection at Tata Memorial Hospital, Parel.

排除标准

  • Patients with other GBC pathologies such as neuroendocrine, sarcomatoid or hepatoid as well as benign pathologies.
  • Macroscopic positive (R2) resections or inoperable disease on surgical exploration.

结局指标

主要结局

to develop a nomogram to predict possibility of ‘futile surgery’ in gallbladder cancers

时间窗: 12 months from the study start date

次要结局

  • To assess disease-free survival, defined as the time from surgery to recurrence or death, will be evaluated.(12 months from the study start date)
  • To assess the overall survival.(12 months from the study start date)

研究者

发起方
Tata Memorial Hospital, Mumbai
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Shraddha Patkar

Tata Memorial Hospital, Mumbai

研究点 (2)

Loading locations...

相似试验